Cerebain Biotech Corp. (“Cerebain” or “the Company”), a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced today that medical device product development company, Sonos Models, Inc. (“Sonos”), has completed Phase 1A of its medical device solution and will begin Phase 1B which will research the Omentum and related patents and literature to obtain a better comprehension of the Omentum as a basis for designing the fluid extraction device.
Cerebain’s President, Gerald DeCiccio, stated “there have been recent public announcements about failed Dementia and Alzheimer's disease drug trials by some of the larger companies. We firmly believe that if we are successful in implementing our approach it could be a game changer in the world of Dementia and Alzheimer's disease.”
In addition, Sonos’s CEO, Carl Tenbrink, stated “we are very excited and vested after completing our initial investigation and exploration into Cerebain’s Omentum project. This is really a leading edge approach to treating Dementia and Alzheimer’s disease using what seems to be an overlooked and poorly understood organ. We look forward to moving into the next phase of product development.”
About Discount Dental Materials, Inc.
Discount Dental Materials, Inc. was incorporated in Nevada on December 17, 2007. The Company’s business involves the discovery of products for the treatment of Alzheimer’s disease utilizing Omentum. The Company’s planned products include both a medical device solution as well as a synthetic drug solution. The Company’s operations are conducted through its wholly-owned subsidiary, Cerebain Biotech Corp. For more information about Discount Dental and Cerebain Biotech, please visit the Company’s website at www.cerebain.com and www.otcmarkets.com, under the ticker symbol “DDOO”, to view the Company’s public filings and stock quote.
About Sonos Models, Inc.
Sonos Models, Inc. has provided industrial design services for 30 years to a wide spectrum of clientele including consumer products, toy, manufacturing, and medical industries. Sonos manages the entire development process from concept to production. The full range of services include conceptual design, engineering, product prototypes, graphic design, e-commerce web design and short run or full production of a product. The latest 3D CAD solid modeling software, Stereolithography, rapid prototype and CNC technology (Computer Numerically Controlled) are utilized to insure that product development and prototype samples are developed with optimum accuracy and efficiency.
Forward Looking Statements
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe,"enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.Business Wire
Last updated on: 02/10/2012
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.